Table 2 Clinical characteristics of participants in the CAD obese, Non-CAD obese, and Non-CAD lean groups in the discovery cohorts
CAD Obs (n = 31) | Non-CAD Obs (n = 28) | P- value | |
|---|---|---|---|
Male, n(%) | 24(77.40) | 16(57.10) | 0.96 |
Age, years | 55.30 ± 6.25 | 53.50 ± 7.16 | 0.34 |
BMI(kg/m2) | 29.50 ± 3.24 | 30.25 ± 2.70 | 0.79 |
Waist(cm) | 101.50 ± 7.60 | 98.80 ± 7.60 | 0.29 |
Hip (cm) | 103.30 ± 6.50 | 102.12 ± 8.00 | 0.64 |
Waist-to-hip ratio | 0.98 ± 0.05 | 0.96 ± 0.04 | 0.32 |
Hypertension status, n (%) | 22(70.90) | 15(53.60) | 0.17 |
Blood pressure, mmHg | |||
Systolic | 135 ± 14 | 131 ± 9 | 0.56 |
Diastolic | 85 ± 8 | 78.45 ± 8 | 0.45 |
Diabetes, n (%) | 15(48.40) | 8(28.50) | 0.12 |
Frequency of current smokers, n (%) | 16(51.60)* | 6(21.40) | 0.02 |
Current alcohol, n(%) | 3(9.60) | 3(10.70) | 0.54 |
CAD family history, n(%) | 7(22.60) | 7(25.00) | 0.83 |
Hyperuricemia, n(%) | 14(45.10) | 14(50.00) | 0.71 |
Total cholesterol, mg/dL | 4.50 ± 0.98 | 4.55 ± 0.96 | 0.83 |
HDL cholesterol,mg/dL | 0.91 ± 0.16* | 1.05 ± 0.31 | 0.01 |
LDL cholesterol, mg/dL | 2.98 ± 0.84 | 2.93 ± 0.98 | 0.19 |
Triglycerides, mg/dL | 1.84 ± 0.89 | 1.45 ± 0.62 | 0.06 |
Alanine aminotransferase (U/L) | 28.23 ± 29.99 | 21.14 ± 11.35 | 0.24 |
HbAc1(%) | 6.45 ± 1.51 | 6.28 ± 1.26 | 0.64 |
Creatinine(umol/L) | 89.16 ± 19.01* | 75.50 ± 16.14 | 0.00 |
Metabolic syndrome | 21(67.74) | 17(60.71) | 0.68 |
Medical use | |||
Anti-platelet | 12(38.70) | 9(29.03) | 0.78 |
Stains | 10(32.25) | 6(21.42) | 0.39 |
β-blockers | 18(58.06) | 10(5.71) | 0.12 |
AECI/ARB | 19(61.29) | 12(42.85) | 0.19 |
Folic acid or VB12 | 0(0.00) | 0(0.00) | - |